Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DTPA-omburtamab in Medulloblastoma
NCT04167618Phase 2Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of 177Lu-DTPA-omburtamab in medulloblastoma, sponsored by Y-mAbs Therapeutics, Inc.. Started Sep 2021; status: terminated.
02
Drugs
177Lu-DTPA-omburtamab
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04167618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167618.